Abstract:Introduction: Target therapy for cancer cell mutation has brought attention to several challenges in clinical applications, including limited therapeutic targets, less patient benefits, and susceptibility to acquired due to their clear biological mechanisms and high specificity in targeting cancers with specific mutations. However, the identification of truly lethal synthetic lethal therapeutic targets for cancer cells remains uncommon, primarily due to compensatory mechanisms. Methods: In our pursuit of core therapeutic targets (CTTs) that exhibit extensive synthetic lethality in cancer and the corresponding potential drugs, we have developed a machine-learning model that utilizes multiple levels and dimensions of cancer characterization. This is achieved through the consideration of the transcriptional and post-transcriptional regulation of cancer-specific genes and the construction of a model that integrates statistics and machine learning. The model incorporates statistics such as Wilcoxon and Pearson, as well as random forest. Through WGCNA and network analysis, we identify hub genes in the SL network that serve as CTTs. Additionally, we establish regulatory networks for non-coding RNA (ncRNA) and drug-target interactions. Results: Our model has uncovered 7277 potential SL interactions, while WGCNA has identified 13 gene modules. Through network analysis, we have identified 30 CTTs with the highest degree in these modules. Based on these CTTs, we have constructed networks for ncRNA regulation and drug targets. Furthermore, by applying the same process to lung cancer and renal cell carcinoma, we have identified corresponding CTTs and potential therapeutic drugs. We have also analyzed common therapeutic targets among all three cancers. Discussion: The results of our study have broad applicability across various dimensions and histological data, as our model identifies potential therapeutic targets by learning multidimensional complex features from known synthetic lethal gene pairs. The incorporation of statistical screening and network analysis further enhances the confidence in these potential targets. Our approach provides novel theoretical insights and methodological support for the identification of CTTs and drugs in diverse types of cancer.

Group-sparse Modeling Drug-kinase Networks for Predicting Combinatorial Drug Sensitivity in Cancer Cells

Prediction of Synergistic Anti-Cancer Drug Combinations Based on Drug Target Network and Drug Induced Gene Expression Profiles

Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway

Network as a Biomarker: A Novel Network-Based Sparse Bayesian Machine for Pathway-Driven Drug Response Prediction

DrugComboRanker: Drug Combination Discovery Based on Target Network Analysis

Predicting drug synergy using a network propagation inspired machine learning framework

Pathway-Guided Deep Neural Network toward Interpretable and Predictive Modeling of Drug Sensitivity

Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations

SYSTEMATIC ASSESSMENT OF ANALYTICAL METHODS FOR DRUG SENSITIVITY PREDICTION FROM CANCER CELL LINE DATA

Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation

Optimizing drug combination and mechanism analysis based on risk pathway crosstalk in pan cancer

Dual-Layer Strengthened Collaborative Topic Regression Modeling for Predicting Drug Sensitivity

How to Predict Effective Drug Combinations - Moving beyond Synergy Scores

SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction

XGraphCDS: An explainable deep learning model for predicting drug sensitivity from gene pathways and chemical structures

Prediction of drug sensitivity based on multi-omics data using deep learning and similarity network fusion approaches

Kinome-wide polypharmacology profiling of small molecules by multi-task graph isomorphism network approach

Quantitative Structure–Mutation–Activity Relationship Tests (QSMART) model for protein kinase inhibitor response prediction

Multi-level characteristics recognition of cancer core therapeutic targets and drug screening for a broader patient population

A novel heterogeneous network-based method for drug response prediction in cancer cell lines

Anti-cancer Drug Synergy Prediction in Understudied Tissues using Transfer Learning